Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema.
Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema.
复制标题
视网膜静脉阻塞患者接受了黄斑水肿的峰值视力丧失。
DOI：
10.1016/j.ajo.2019.03.029
复制
发表时间：
2019-09
影响因子：
4.2
通讯作者：
Campochiaro, Peter A.
中科院分区：
文献类型：
--
作者：
Iftikhar, Mustafa;Mir, Tahreem A.;Hafiz, Gulnar;Zimmer-Galler, Ingrid;Scott, Adrienne W.;Solomon, Sharon D.;Sodhi, Akrit;Wenick, Adam S.;Meyerle, Catherine;Jiramongkolchai, Kim;Liu, T. Y. Alvin;Arevalo, J. Fernando;Singh, Mandeep;Kherani, Saleema;Handa, James T.;Campochiaro, Peter A.
评估接受抗血管内皮生长因子 (VEGF) 药物治疗的视网膜静脉阻塞 (RVO) 患者的长期视觉和解剖结果。前瞻性、介入性病例系列。患有中央 RVO (CRVO) 或分支 RVO (BRVO) 的患者。前瞻性记录了 39 名 CRVO 患者的 40 只眼睛和 47 名 BRVO 患者的 50 只眼睛的抗 VEGF 注射次数以及相对于基线最佳矫正视力 (BCVA) 和中心子视野厚度 (CST) 的改善。 BRVO 的平均随访时间为 58 个月，CRVO 的平均随访时间为 78 个月。末次随访6个月内，58%的BRVO患者和75%的CRVO患者需要注射抗VEGF药物来控制水肿。对每位患者随时间的病程分析表明，对于 BRVO 患者，BCVA 字母评分平均增加 24，从基线 52 (20/100) 到峰值 76 (20/32)，随后在最终就诊时下降 13，至 63 (20/50)；对于 CRVO 患者，BCVA 字母评分从基线 48 (20/100) 平均增加 26 分至峰值 74 (20/32)，随后在最后一次随访时下降 18 分至 56 (20/80)。最佳最佳矫正视力 (BCVA) 峰值下降主要是由于持续/复发性水肿和相关的中心凹损伤。 RVO 患者在开始注射抗 VEGF 后，最佳矫正视力 (BCVA) 显着改善，但许多患者由于反复出现水肿，随着时间的推移，一些视力增益会丧失。持续抑制 VEGF 可能有助于在 RVO 中提供最佳结果并减轻治疗负担。
To evaluate long-term visual and anatomic outcomes in patients with retinal vein occlusion (RVO) treated with anti–vascular endothelial growth factor (VEGF) agents. Prospective, interventional case series. Patients with central RVO (CRVO) or branch RVO (BRVO). Number of anti-VEGF injections and improvement from baseline best-corrected visual acuity (BCVA) and central subfield thickness (CST) were prospectively recorded in 40 eyes of 39 CRVO patients and 50 eyes of 47 BRVO patients. Mean follow-up was 58 months for BRVO and 78 months for CRVO. Within 6 months of last follow-up, 58% of BRVO patients and 75% of CRVO patients required anti-VEGF injections to control edema. Analysis of the course of each patient over time showed that for BRVO patients, BCVA letter score increased by a mean of 24, from baseline of 52 (20/100) to peak of 76 (20/32), and subsequently decreased by 13, to 63 (20/50), at final visit; and for CRVO patients, BCVA letter score increased by a mean of 26, from baseline of 48 (20/100) to peak of 74 (20/32), and subsequently decreased by 18, to 56 (20/80), at last follow-up. Loss from peak BCVA occurred primarily owing to persistent/recurrent edema and related foveal damage. Patients with RVO showed large improvements in BCVA after initiation of anti-VEGF injections, but in many patients some visual gains were lost over time owing to bouts of recurrent edema. Sustained suppression of VEGF may help to provide optimal outcomes in RVO and reduce treatment burden.
登录
查看更多内容
影响因子：
3.7
作者：
Saint-Geniez M;Maharaj AS;Walshe TE;Tucker BA;Sekiyama E;Kurihara T;Darland DC;Young MJ;D'Amore PA
通讯作者：
D'Amore PA
影响因子：
13.7
作者：
Heier, Jeffrey S.;Clark, W. Lloyd;Haller, Julia A.
通讯作者：
Haller, Julia A.
影响因子：
8
作者：
Long, Da;Kanan, Yogita;Campochiaro, Peter A.
通讯作者：
Campochiaro, Peter A.
影响因子：
12.4
作者：
Campochiaro, Peter A.;Hafiz, Gulnar;Arron, Joseph R.
通讯作者：
Arron, Joseph R.
影响因子：
13.7
作者：
Campochiaro, Peter A.;Clark, W. Lloyd;Haller, Julia A.
通讯作者：
Haller, Julia A.